Press Releases

Apr 10, 2021
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells New TurboCAR Constructs Can Be Induced by Binding To PDL1/2, Making Cytokine Activation Dependent Upon the Tumor Microenvironment and Overcoming PDL1/2 Inhibition Results
Displaying 21 - 26 of 26
Print Page
Email Alerts
RSS Feeds
Investor Contacts